ArticleBMC cancer2025
Trend analysis of cancer mortality and years of life lost in the South of Iran 2004-2019. Joinpoint regression analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is the second leading cause of death globally and is a significant financial burden on public health systems. This study aimed to investigate cancer mortality trends and years of life lost (YLL) in Fars province.
methodThe data on the total number of deaths caused by cancer in Fars Province was collected from the Electronic Population-Based Death Registration System (EDRS). Various statistics such as crude and age-standardized mortality rates, YLL, and YLL rates were computed. To analyze the trend, the JoinPoint Regression method was utilized.
resultsOver a period of 16 years (2004–2019), there were 31,669 recorded deaths in Fars province. Of these, 59.4% (18806 cases) were male. The trend in age-standardized mortality rate (ASMR) rose for both males and females. The annual percent change (APC) was 1.3 (0.6 to 2.1, P for trend = 0.002) for males and 1.8 (0.8 to 2.9, P for trend = 0.001) for females. During the 16-year study period, the total YLL was 247,035 (7.8 per 1000 people) in males and 202,037 (6.6 per 1000 people) in females. The highest number of YLL in males due to cancer was caused by leukemia and lymphoma (13.3%), stomach (13.1%), and lung (11.4%). In females, the highest number of YLL due to cancer was caused by breast (16.4%), leukemia and lymphoma (11.4%), and stomach (9.9%). Based on the join point regression analysis, the rate of YLL due to premature mortality increased during the 16-year trend: APC was 2.3% (95% CI 1.8 to 2.8, p<0.001) for males and 3.5% (95% CI 2.7 to 4.4, p<0.001) for females.
conclusionThe crude, standardized mortality rates and years of life lost (YLL) due to cancer have been increasing in both males and females. As a result, public health programs and research funding should be more explicitly directed towards preventing premature mortality. YLL can be a useful measure for easy comparison of different cancers by policymakers and health practitioners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.